Imagine if we could find a tiny needle in a haystack by looking for a few specific grains of sand. This project creates a blood test that spots the earliest signs of pancreatic cancer by searching for a mix of DNA and proteins. It uses AI to make sure the test is accurate, avoiding false alarms while catching the disease early enough to actually treat it.
Pancreatic cancer is usually found too late, leading to most patients dying within one year. Current tests often lack the sensitivity to find small tumors or the specificity to avoid costly false positives.
A multi-biomarker blood test panel and an AI-assisted computational analysis tool for early PDAC detection.
If you are a diagnostic company dealing with low sensitivity in early cancer detection — this project developed a multi-biomarker panel that integrates DNA, proteins, and metabolites. This allows for a high-accuracy test that reduces the risk of overdiagnosis and unnecessary healthcare costs.
If you are a software firm dealing with the complexity of multimodal health data — this project developed an AI-assisted computational analysis tool. It integrates various biological features to identify the best composite biomarker panel for early diagnosis.
If you are a clinic dealing with high-risk patient screening — this project developed a validated blood-based test design. This enables the introduction of screening programs for high-risk individuals to detect precursor lesions before they become fatal.
Based on available project data, the specific price per test is not mentioned; however, the project analyzes the socio-economic impact to reduce high costs for the health system caused by false positives.
The project is designing a future prospective study for international multi-center validation, which is a prerequisite for introducing these tests into large-scale screening programs.
Based on available project data, specific licensing terms are not provided, but the project involves 4 industry partners who are contributing to the development of the biomarker panel.
The project runs from 2023-01-01 to 2027-12-31, with the first 3 years dedicated to training and panel determination, followed by validation in years 4 and 5.
The test is designed as a liquid biopsy (blood test), intended for use in screening programs for high-risk individuals within existing healthcare models.
The consortium is heavily research-driven with 12 universities and 2 research institutes, but it maintains a strategic 18% industry ratio with 4 industrial partners, including 2 SMEs. This balance suggests a strong academic foundation for biomarker discovery with a clear path toward commercial application through the included industry players across 8 countries.
Contact Universitaetsklinikum Hamburg-Eppendorf
Contact us to explore licensing opportunities for the AI-biomarker panel.
